Swiss National Bank Has $19.46 Million Stake in DaVita Inc. (NYSE:DVA)

Key Points

• The Swiss National Bank reduced its stake in DaVita Inc. by 2.4%, selling 3,100 shares, leaving it with approximately 127,200 shares valued at around $19.46 million.
• Institutional investors hold about 90.12% of DaVita's stock, with notable positions increasing in the first quarter, such as UMB Bank's stake growing by 65.5%.
• Analysts are optimistic about DaVita's growth, with a target price set at $148.00 by Truist Financial and various analysts upgrading its rating from "hold" to "buy."

Swiss National Bank decreased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 2.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 127,200 shares of the company's stock after selling 3,100 shares during the period. Swiss National Bank owned 0.17% of DaVita worth $19,458,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DVA. Epoch Investment Partners Inc. bought a new stake in DaVita during the fourth quarter worth approximately $55,100,000. Iron Triangle Partners LP bought a new stake in DaVita during the fourth quarter worth approximately $38,946,000. GAMMA Investing LLC raised its holdings in DaVita by 14,695.8% during the first quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after purchasing an additional 233,222 shares in the last quarter. Bridgewater Associates LP raised its holdings in DaVita by 298.4% during the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock worth $35,888,000 after purchasing an additional 179,744 shares in the last quarter. Finally, Rovin Capital UT ADV bought a new position in shares of DaVita in the first quarter valued at $18,442,000. Institutional investors own 90.12% of the company's stock.

DaVita Trading Up 0.7%

NYSE DVA traded up $0.96 on Friday, hitting $135.35. 721,001 shares of the stock were exchanged, compared to its average volume of 925,075. DaVita Inc. has a 52-week low of $126.07 and a 52-week high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.39 and a quick ratio of 1.34. The company has a market capitalization of $9.68 billion, a price-to-earnings ratio of 13.31, a P/E/G ratio of 0.97 and a beta of 1.09. The company's 50-day moving average price is $139.68 and its two-hundred day moving average price is $145.28.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. During the same period in the previous year, the company posted $2.00 EPS. The company's quarterly revenue was up 6.1% compared to the same quarter last year. Research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

Insider Activity at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Truist Financial set a $148.00 price target on DaVita in a report on Friday, August 8th. Barclays dropped their price target on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.